Nodal Marginal Zone Lymphoma Clinical Trials

18 clinical trials for Nodal Marginal Zone Lymphoma across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma — RECRUITING
• Study of SGR-1505 in Mature B-Cell Neoplasms — RECRUITING · PHASE1
• Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. — RECRUITING · PHASE1
• Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) — RECRUITING · PHASE2
• Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma — NOT_YET_RECRUITING · PHASE2
• MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas — ACTIVE_NOT_RECRUITING · PHASE2
• Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma — COMPLETED · PHASE2
• Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors — COMPLETED · PHASE1
• Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma — COMPLETED · NA
• Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma — COMPLETED · PHASE2
• Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma — COMPLETED · PHASE1
• Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma — COMPLETED · PHASE2
• Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphoma — COMPLETED · PHASE3
• Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers — COMPLETED · PHASE1
• Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma — COMPLETED · PHASE1
• Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection — TERMINATED · PHASE1
• Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery — COMPLETED · PHASE1
• Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms — COMPLETED · PHASE1

Refine this search